IMRT-based optimization approaches for volumetric modulated single arc radiotherapy planning by Crijns, Wouter et al.
Radiotherapy and Oncology 95 (2010) 149–152Contents lists available at ScienceDirect
Radiotherapy and Oncology
journal homepage: www.thegreenjournal .comVolumetric modulated arc therapy
IMRT-based optimization approaches for volumetric modulated single arc
radiotherapy planning
Wouter Crijns *, Tom Budiharto, Gilles Defraene, Jan Verstraete, Tom Depuydt, Karin Haustermans,
Frank Van den Heuvel
Department of Radiotherapy, University Hospital Leuven, Belgium
a r t i c l e i n f o a b s t r a c tArticle history:
Received 23 July 2009
Received in revised form 8 January 2010
Accepted 17 January 2010
Available online 18 February 2010
Keywords:
RapidArc
VMAT
Dose escalation
Prostate cancer0167-8140/$ - see front matter  2010 Elsevier Irelan
doi:10.1016/j.radonc.2010.01.012
* Corresponding author. Address: University Hosp
Radiotherapy, Herestraat 49, 3000 Leuven, Belgium.
E-mail address: wouter.crijns@uz.kuleuven.be (W.This paper reports on an evaluation of 5 RapidArc optimization approaches vs IMRT. This study includes
11 patients with adenocarcinoma of the prostate. Rectal Normal Tissue Complication Probability is used
as a constraint in a dose escalation. RapidArc rectal NTCP’s are lower than those of IMRT (p = 0.007). This
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 2010 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 95 (2010) 149–152Several treatment planning studies confirm a significant
improvement in organ at risk (OAR) sparing using a RapidArc
(RA) technique instead of intensity modulated radiation therapy
(IMRT). RA reaches this OAR protection without the loss of a suffi-
cient target coverage [1,2]. An additional advantage in comparison
with IMRT is the reduction of treatment time. However, the
treatment planning and optimization are more time consuming.
Our aim is to use Adjusted IMRT Optimization Objectives (AIOOs)
for RA optimization for the treatment of prostate cancer patients.
The AIOOs are designed to be used without user interaction during
optimization, in order to avoid the time consuming disadvantage
of the RA optimization. As a secondobjective, the effect of collimator
angle,maximumalloweddose rate, and theuseofmultiple PTV-sub-
volume shells – with individual constraints – are evaluated.Materials and methods
Patients
Eleven patients with a biopsy-proven diagnosis of adenocarci-
noma of the prostate are selected for this planning study. Before
planning CT acquisition, four cylindrical gold markers are inserted
transrectally into the prostate under ultrasound guidance, to serve
as image-guided radiotherapy fiducials [3,4].d Ltd. All rights reserved.
ital Leuven, Department of
Crijns).Planning
The treatment planning CT is acquired at least one week after
marker implantation, in order to reduce the possible swelling
caused by inflammation and/or bleeding. Patients are imaged in a
supine position, with a solid foam wedge between the patient’s
feet.
Immediately following the CT-simulation a T2-weighted MRI is
performed. MR and CT images are registered rigidly using a mutual
information algorithm available in Eclipse™ (Varian Medical
Systems, Palo Alto, California, USA).
On the axial MR images the prostate and seminal vesicles are
contoured as target volumes while bladder, rectum, anal canal
and penile bulb are defined as OAR. Contouring is performed by
a single radiation oncologist following the standardized guidelines.
The femoral heads are contoured on the CT images.
For each patient, six plans are created: a static gantry IMRT plan
and five RA plans using different optimization methodologies as
explained below.
The plan normalization is performed using the PTV prostate
mean dose (VPTV = 154.7 ± 58.3 cc). The PTVs are created using iso-
tropic margins of 1 and 0.5 cm for, respectively, the prostate and
the seminal vesicles. In the overlap between PTVs of the prostate
and seminal vesicles, priority is given to the prostate PTV. A Simul-
taneous Integrated Boost (SIB) technique is used, to deliver 74 Gy
(2 Gy/fraction) to the PTV prostate and 55.5 Gy (1.5 Gy/fraction)
to the PTV seminal vesicles. Table 1 summarizes the planning
objectives.
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150 IMRT-based VMAT planning optimizationOptimization
The RA optimization as implemented in Eclipse™ allows user
interactionduring theprocess. However, in this study the priorities,
volumepercentages, andthedosevaluesarekeptconstant toensure
an objective comparison of the different RA planning approaches. A
second advantage of this approach is ‘‘the gain of the operators
time”, his/her presence during optimization is no longer required.
The AIOO is based on the plan objectives of Table 1. A selection of
the volume percentages of Table 1, Vi, and their related dose values,
DTable,i, are comparedwith the respectivedose values fromthe IMRT
plan,DIMRT,i. AnAIOO is the combinations of the volumepercentage,
Vi, and the associated tolerance doses DRA,i from Eq. (1).
DRA;i ¼ 0:9minðDIMRT;i;DTable;iÞ ð1Þ
The arbitrary choice of the multiplicative factor 0.9 is based on our
first planning experience. It is a method to create a proper input for
the RA optimizer, without losing our IMRT experience. A first
advantage of the AIOO in Eq. (1) is the limited user dependency.
It only depends on the creation of the IMRT plan, which is user
dependent. A second advantage is the automated calculation of
the optimization objectives. For this study a home-made script
(Matlab, The MathWorks, Inc.) calculates the AIOOs after a dicom
export DVH of the IMRT plan.
A disadvantage is the necessity to create an IMRT plan. Future
work lies in pre-calculating an average hDIMRT,ii. This requires an
enlarged patient group as well as a verification patient group.
Replacing DIMRT in Eq. (1) by hDIMRT,ii then results in fixed optimi-
zation objectives.
The AIOOs are used to create all five RA approaches for eleven
different patients. The geometrical optimization, which optimizes
collimator rotation and field size, is not used. The normal tissue
objective is used to protect healthy tissue. The field size is arbi-
trarily determined in the beams eye view of the starting gantry
angle using a 7 mm distance to the target volume (PTV prostate
[ PTV seminal vesicles). The 7 mm distance is a common use at
our department for static beams. The gantry moves counter clock-
wise from 179 to 181. RA is described as an extension of IMRT
[10]. Our clinical IMRT routine has a maximal dose rate of
300 MU/min, to ensure adequate leaf motion. Therefore the de-
fault maximal RA dose rate is set to 300 MU/min. The five RA
planning approaches are described below:
(A) Has thecollimator rotationset to45beforedeterminationof
themaximalfield size. The choiceof the collimator angle is to
avoid a cumulative impact of tongue and groove effects.
(B1) Like (A) with a 5 collimator rotation. Using this collimator
rotation the multileaf collimator (MLC) moves more per-
pendicularly to the rectum. The intention is to obtain an
alignment of leaves for better rectal protection, while still
avoiding the aforementioned tongue and groove effects.
(B2) Like (B1) with a 95 collimator rotation. This collimator
rotation minimizes the number of leaves providing rectal
protection. Additionally the number of leaves involved in
the dose modulation is increased.
(C) Like (A) but the prostate PTV is divided into three shell-like
subvolumes. The first prostate subvolume is the outer
7 mm shell of the prostate. The second prostate shell is
the next 7 mm and the remainder forms the third shell.
The seminal vesicles are divided into an outer 7 mm shell
and an inner part. The PTV prostate constraints listed in
Table 1 are used on each of the PTV prostate subvolumes.
For the PTV seminal vesicles the same procedure is used.
This ‘‘shell model” is introduced to increase control on dose
homogeneity.
(D) Like (A) but the maximum dose rate is increased to
600 MU/min.
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For all approaches dose values are determined for each of the
volume percentages listed in Table 1. The mean of these dose val-
ues are compared to the reference values (listed in Table 1). An un-
paired t-test (a = 0.05) is used. When the right/left tailed test fails
the lower/upper limit of the 95%-confidence interval is printed in
Table 1.
Normal tissue complication probabilities (NTCPs) for rectum
and bladder are calculated using the relative seriality model, pre-
dicting late toxicity:
Rectum Grade 2 or higher rectal bleeding; D50 = 83.1 Gy,
c = 1.69, s = 0.49 [11].
Bladder Contracture and volume loss; D50 = 80.3 Gy, c = 3,
s = 1.3 [12],
where D50 is the dose resulting in 50% complication probability, c
provides the maximal slope of the dose–response relation and s
describes the functional architecture (relative seriality) of the
organ. DVH’s are corrected for fractionation using a biological
effective dose (BED) methodology with ab ¼ 3. Using a rectal iso-
NTCP a target dose escalation is performed. For all patients the
dose of approach (A) is escalated by increasing the delivered dose
until the rectal NTCP of the IMRT plan is reached.
Tumor control probabilities (TCP, ab ¼ 3 [13]) for the prostate
PTV were calculated following the approach proposed by Webb
and Nahum [14]. To split the DVHs into subvolumes, a normal dis-
tribution decomposition is used [15].
The conformality index is defined as: CI95% ¼ V95%VPTV . The dose
homogeneity is defined as: H ¼ 100  1 D5%D95%Dmean
 
.
SD is the PTV prostate dose standard deviation. T1 is the treat-
ment time (beam on time). T2 is the fraction of T1 with gantry
speed modulation. CI95%, H, SD, T1, T2, and the NTCP’s are used for
comparison between different planning approaches (paired t-test,
a = 0.05).1
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Fig. 1. TCP’s for: IMRT, method A, and method A after dose escalation based on iso-
rectal NTCP’s. Dose after escalation is indicated for every patient.Results (summarized in Table 1)
Dose constraints
The PTV D95% of approach B2 is significantly smaller than the
constraint and significantly smaller than all other approaches,
however there are no significant differences in TCP. The PTV D95%
of approach B1 is significantly smaller than the IMRT approach
but still within constraints. For the OAR the RA approaches are sim-
ilar to the IMRT approach. The most significant difference is in the
maximal dose. Only RA approach B1 meets the PTV maximal dose
constraint, but the maximal dose of approach B1 is still signifi-
cantly larger than the maximal dose of the IMRT approach.
The seminal vesicles V95%  D95%-constraint is not met for all RA
approaches. The failure on the V95%  D95%-constraint for the sem-
inal vesicles is caused by the low optimization objective on 95% of
the seminal vesicles. There are no significant differences among the
RA approaches.
For all five RA planning approaches the rectal maximum dose is
not smaller than the constraint. The goal of approaches B1 and B2
is to avoid the high doses which are found in the caudal part of the
field. Using this collimator rotation the leaf motion is more perpen-
dicular or parallel to the rectum. This makes it easier to protect the
rectum and results in lowered maximum rectal doses. The maxi-
mum rectal dose of approach B1 is significantly smaller than those
of approaches A and C. The maximum rectal dose of approach B2 is
significantly smaller than those of approaches A, C, and D.
The maximal dose to the anal sphincter is lower than the con-
straint for all plans except when using approach D. The mean dose,V40%-dose for the anal sphincter, and the rectal V85%-dose have no
significant differences among all planning approaches.NTCP–TCP
Themeanof the rectal NTCP is significantly smallerwith RA com-
pared to IMRT. The mean value over all patients for rectal NTCP de-
creases from 2.2% with IMRT to 1.8% with RA approach A. This
NTCP value is lower using RA in 9 of 11 individual cases leading to
a highly significant difference between the techniques (p = 0.007).
Only RA approach D differs significantly (p = 0.034) from approach
A. RA does not performbetter than IMRTwith regard to bladder tox-
icityexcept for approachB2. TheTCPvalues for IMRTandRAplansdo
not differ significantly.Dose escalation
A mean dose escalation of 2.1 Gy (CL95% = [0.7 Gy, 3.5 Gy]) is
possible based on iso-rectal NTCP’s for IMRT plans and RA ap-
proach A plans. This results in one additional 2 Gy-fraction for 5
of 11 patients, two additional fractions for two of them and three
additional fraction for one of these two. This leads to improvement
of the prostate-TCP as illustrated in Fig. 1. The resulting higher
bladder NTCP with escalation is considered of minor importance.Conformality and homogeneity
Only the conformality of B1 differs significantly from IMRT.
However, B1 has a reduced homogeneity compared to the other
RA approaches. The IMRT approach is significantly more homoge-
nous than the RA approaches. The mean value of the target dose
(PTV prostate) SD is significantly larger using approach B2. Ap-
proaches A and B1 have larger SD’s than IMRT. No other significant
differences are noted.Time
The use of 600 MU/min (D) results in the smallest treatment
times (T1). It also has the smallest fraction (T2) of gantry speed
modulation. Only for one patient approach D results in a short per-
iod with modulated gantry speed. Approach A has significantly
more gantry speed modulation. Approach C has significantly more
gantry speed modulation than approach B2. No other significant
differences are noted.
152 IMRT-based VMAT planning optimizationDiscussion
RA planning studies in the pelvic region are published by Palma
et al. and Cozzi et al. [1,2]. In these studies RA plans are superior to
IMRT, with better rectal protection as is confirmed in the present
study. The RA optimization approaches show lowered rectal-
NTCPs, despite an increase of the maximal rectal dose. The use of
approaches B1 and B2 to protect the rectum by perpendicular/par-
allel leaves show better results with respect to maximal dose for
prostate and rectum. The slightly worse result on PTV seminal ves-
icles V95%–D95% can be compensated with a slight alteration to the
AIOO. On the other hand the homogeneity of these RA plans is
slightly worse than our IMRT-practice, while Palma et al. and Cozzi
et al. report equally good homogeneity. Approaches C and D in-
crease control on the target dose standard deviation.
However, the comparison presented here is between the use of
the first version of the RA optimizer and our IMRT experience span-
ning several years. The homogeneity will probably improve in the
next releases, which include simultaneous optimization of multi-
ple arcs. Wolff et al. ([16]) report better homogeneity using more
than 360 VMAT. Guckenberger et al. ([17]) relates the number of
arcs to the number of dose levels in a SIB. For prostate cases with
two dose levels an increase in homogeneity is noticed using double
arcs instead of single arc VMAT.
Deceleration of the gantry from its maximal speed is only done
when the maximal dose rate is reached. A minimal fraction of the
beam with gantry speed modulation (deceleration) indicates less
(intensity) modulation in the plan. Therefore, the significant reduc-
tion of T2 for approaches B1, B2, and C compared to approach A,
proves a reduction in modulation and the usefulness of the alterna-
tive collimator rotation and the homogeneity structures.
Approach A leads on average to acceptable plans (t-tests on the
dose constraints). In clinical practice, when a specific case does not
meet the constraints sufficiently an additional optimization is per-
formed. In this extra optimization the AIOOs are adjusted to fit the
specific situation.
In this way two or three optimizations (1  IMRT and 1 or
2  RA) lead to an acceptable treatment plan. However, we strive
to achieve a fully non-interactive optimization approach for RA
treatment planning for prostate cancer patients using AIOO. This
non interactive optimization could be based on a combination of
planning approaches B1, B2, C, and D, which will likely lead to an
escalated target dose.
Conclusion
Patient specific optimization objectives are introduced and
compared with 5 RA planning approaches. Apart from an objective
comparison and automated calculation of these objectives the
AIOO ensures a limited user dependency and a time gain. Different
approaches are proposed to increase control on the maximal dose
(approaches B1 and B2), and to increase control on dose homoge-
neity (approach C). All presented RA planning approaches result
in better rectal protection (lowered NTCP) and make dose escala-tion possible. Additionally the suggested approaches B1, B2, C
and D reduce modulation. Therefore the presented approaches,
using AIOO, are a powerful tool for introducing RA in clinical prac-
tice starting from an IMRT experience.
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